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MaOBJECTIVES The purpose of this study was to test whether adaptive or maladaptive remodeling is associated
with survival in women and men after aortic valve replacement (AVR).
BACKGROUND Women with isolated aortic valve stenosis (AS) develop more concentric left ventricular hypertrophy
(LVH) than men in similar disease states. We recently reported less up-regulation of proﬁbrotic genes at AVR and faster
LVH regression post-operatively in women than in men, suggesting that there are sex differences in the adaptation to
pressure overload and its regression.
METHODS The study cohort included 128 patients (age 70.0  9.6 years, 49% women) undergoing AVR for AS. Echocar-
diography was obtained before and 4.0 1.6 years after surgery. Factor analysis was used to classify LVH as adaptive
(combiningsmaller left ventricular [LV]mass/diametersandgreater relativewall thicknesses) ormaladaptive.Myocardial tissue
samples from the LV septum were obtained during AVR to analyze cardiac ﬁbrosis and associated key molecular regulators.
RESULTS Before AVR, LVH was classiﬁed as adaptive in 62% of women and 45% of men (p < 0.050). Four years after
AVR, adaptive LVH was observed in 75% of women and 49% of men (p < 0.031). At surgery, more cardiac ﬁbrosis was
present in men compared with women (p < 0.05). Higher levels of transforming growth factor beta 1 (p < 0.01), SMAD2
phosphorylation (p < 0.001), and periostin expression (p < 0.05) were found in men than in women. Women with
maladaptive LVH had worse survival than women with adaptive LVH (p < 0.050), whereas the pattern of LVH did
not affect survival in men (p < 0.307).
CONCLUSIONS Women more frequently exhibit adaptive LV remodeling with less ﬁbrosis than men. Maladaptive
LVH is associated with worse survival in women. Thus, sex should be considered as a strong modulating factor when
management of patients with AS is discussed. (J Am Coll Cardiol Img 2014;7:1073–80) © 2014 by the American College
of Cardiology Foundation.A ortic stenosis (AS) is a common valvular dis-ease that affects both sexes. More than12,000 patients undergo aortic valve replace-
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ABBR EV I A T I ON S
AND ACRONYMS
AS = aortic stenosis
AVR = aortic valve
replacement
LV = left ventricle
LVH = left ventricular
hypertrophy
LVID(d) = left ventricular
internal diameter at
end-diastole
PO = pressure overload
RWT = relative wall thickness
SMAD2/3 = SMAD family
member 2 or 3
TGF-ß1 = transforming growth
factor beta 1
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1074function of the heart. However, pressure-
induced LVH also initiates a series of molecu-
lar events that may lead to a vicious circle and
ﬁnally to myocardial ﬁbrosis, dilation, and
heart failure (2). LVH is not uniform in pa-
tients with a similar degree of AS, and its
regression after surgical correction is vari-
able. Genetic predisposition of the patient
probably interferes with hemodynamic load
to determine the pattern of LVH, its regres-
sion, and clinical course after surgery (3,4).
Sex has been described to have a major
impact on the development of LVH in pres-
sure overload (5,6). Women with AS develop
a more concentric form of LVH with smaller
ventricular diameters, greater relative wall
thicknesses, and a better systolic function,whereas men with comparable degree of pressure
overload are characterized by a more eccentric form
of LVH with more ventricular dilation and ﬁbrosis,
decreased ejection fraction, and heart failure (7). Our
own previous investigations in patients with AS
showed at the time of AVR higher messenger ribo-
nucleic acid expression of ﬁbrosis-associated genes,
that is, collagen I and III, MMP-2, and MMP-9, in men
compared with women (8).SEE PAGE 1081Relief of mechanical obstruction by AVR leads to
hemodynamic improvement and reversal of LVH.
Sufﬁcient evidence exists that LVH regression not
only is a passive process, triggered by reduction in
afterload, but also requires an activation of a speciﬁc
gene expression program (9). Regression of LVH
starts early after AVR but may go on for years (10).
Even though the time course of hypertrophy regres-
sion has been extensively studied, few studies have
considered the inﬂuence of sex on the post-operative
reversibility of LVH, and the overall evidence of sys-
tematic sex differences remains limited (8,11). We
recently demonstrated that early LVH regression after
AVR is more pronounced in women than in men (8).
Survival after AVR depends on a number of clinical
variables, including pattern of pre-operative LVH,
severity of myocardial dysfunction, and cardiac
ﬁbrosis (12). There are only few studies analyzing sex
differences in the post-operative survival after AVR
(13–15). Linking sex differences in pre-operative LVH
to regression and survival after AVR may improve our
understanding of their relevance and offer new hints
for optimal timing of interventions. We, therefore,
continued our previous investigations on sex-speciﬁc
LVH regression after AVR (8). The present study was
undertaken to assess whether the pattern ofmyocardial adaptation in women and men with AS is
associated with long-term survival after AVR.
METHODS
We included patients who were hospitalized at the
German Heart Institute Berlin for AVR due to isolated
AS. Exclusion criteria were emergency surgery, sec-
ond AVR, transcatheter aortic valve implantation, left
ventricular (LV) ejection fraction #40%, coronary
artery narrowing $50%, coincident signiﬁcant con-
genital or acquired valvular defects other than AS,
pre-existing inﬂammatory heart diseases, cardiomy-
opathies, uncontrolled hypertension (blood pressure
$160/$100 mm Hg) or other extracardiac comorbid-
ities (i.e., human immunodeﬁciency virus, metabolic
disorders, malignancies, and so on), or language
problems that might affect the clinical outcome or
limit informed consent. The study was started in 2005;
patients were followed prospectively and invited be-
tween 2011 and 2012 for follow-up echocardiography.
The initial response rate was 83%. In follow-up re-
sponders, reasons for refusal to participate in echo-
cardiography included residency abroad or in other
federal states of Germany (n ¼ 10), physical invalidity
(n ¼ 5), death before follow-up was conducted (n¼ 19),
or refusal without indication of reasons (n ¼ 4). Car-
diac morphology and function were assessed about a
week before AVR and 4.0  1.6 years post-operatively,
following the recommendations of the American So-
ciety of Echocardiography (16). Follow-up echocardi-
ography was obtained in a representative subgroup of
68 survivors (43% women; p < 0.097 for sex differ-
ence; see Online Table S1-A for patients’ characteris-
tics), and the cumulative hazard to have an
echocardiography at follow-up did not vary between
women and men (p< 0.117). Written informed consent
was obtained from all patients, and the study was
approved by the ethical committee of Charité Uni-
versitaetsmedizin Berlin.
Mean overall follow-up was 3.2 years in women
(95% conﬁdence interval [CI]: 2.7 to 3.7 years) and 2.9
years in men (95% CI: 2.5 to 3.4 years, p < 0.362).
Primary clinical endpoints were LVH regression and
death. Before the study database was closed in
December 2012, a query to all local residents’ regis-
tration ofﬁces (all residents in Germany are regis-
tered) was performed to assign unknown deaths.
Myocardial tissue samples were harvested from the
LV septum during AVR in a representative subgroup
of 43 AS patients (49% women; see Online Table S1-B
for patients’ characteristics) and compared with LV
septum biopsies from nondiseased donor hearts (n ¼
23; 52% women, see Online Table S2 for nondiseased
TABLE 1 Baseline Characteristics of the Study Population
Women
(n ¼ 63)
Men
(n ¼ 65) p Value
Age at AVR, yrs 71  9 70  10 0.457
BSA, m2 1.8  0.2 2.0  0.2 <0.001
Obesity 33 35 0.807
GFR (Cockroft-Gault), ml/min 69  21 84  26 0.001
Syncope 24 18 0.458
Dyspnea at exertion 83 82 0.883
Dyspnea at rest 11 6 0.317
NYHA functional class II/III 83 85 0.158
Hypertension 86 89 0.548
Hyperlipidemia 60 58 0.831
Diabetes mellitus 27 31 0.637
Coronary artery sclerosis* 2 11 0.062
Chronic obstructive pulmonary disease 13 17 0.502
Cerebrovascular accident 8 3 0.270
Beta-blockers 48 49 0.855
ACE inhibitors 44 40 0.611
Prosthesis type
Mechanical 8 21 0.050
Biological 92 79 0.018
Prosthesis EOA, cm2 1.3  0.1 1.5  0.4 <0.001
Prosthesis EOA/BSA, cm2/m2 0.7  0.1 0.7  0.2 0.209
Prosthesis-patient mismatch
Nonsigniﬁcant 7 10 0.744
Moderate 72 63 0.323
Severe 21 27 0.461
Values are mean  SD or %. Bold values indicate statistical signiﬁcance. *Coronary artery
sclerosis is deﬁned as lumen obstruction #50%.
ACE ¼ angiotensin converting enzyme; AVR ¼ aortic valve replacement; BSA ¼ body surface
area; EOA ¼ effective oriﬁce area; GFR ¼ glomerular ﬁltration rate; NYHA ¼ New York Heart
Association.
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1075subjects’ characteristics) that could not be used for
transplantation because of age or logistic problems
with the recipients. Fibrosis was quantitated by his-
tology; transforming growth factor beta-1 (TGF-b1),
SMAD family member 2 or 3 (SMAD2/3), and periostin
protein expression by western blotting (see the
Online Appendix for details). Detailed methodology
has been described previously (17,18).
Statistics were performed using SPSS Statistics,
version 21 (IBM, Armonk, New York). All of the data in
the tables are presented as mean  SD or percentages
unless otherwise indicated. Sex comparisons were
performed using unpaired Student t test or Mann-
Whitney U test as appropriate. Categorical variables
were tested using Pearson chi-square test. Two-way
analysis of variance with Bonferroni post hoc testing
was used to assess sex differences in cardiac ﬁbrosis
and associated key molecular regulators of patients
with AS versus samples from nondiseased hearts.
Kaplan-Meier and Cox models were used to analyze
the survival data. Comparisons of survival curves
were on the basis of the Breslow test. A value of
p < 0.05 was considered statistically signiﬁcant.
Factor analysis including LV mass, left ventricular
internal diameter at end-diastole (LVID[d]), relative
wall thickness (RWT), transvalvular or transpros-
thetic mean pressure gradient (Pmean) and peak
pressure gradient (Ppeak), as well as body size and
mass was used to analyze LVH under conditions of
chronic PO and its regression after AVR. The factor
analysis identiﬁed 1 multidimensional index for LVH
(LVH index), 1 for PO (PO index), and 1 for body size
and mass. The LVH index was correlated with LV
mass (factor loading 0.676) and LVID(d) (factor
loading 0.937) and inversely correlated with RWT
(factor loading 0.861). The PO index was correlated
with Pmean (factor loading 0.971) and Ppeak (factor
loading 0.970). The body size and mass index was
correlated with height (factor loading 0.856) and
weight (factor loading 0.839). Because the factor
analysis was conducted as a principal component
analysis, the LVH, PO, and body size and mass in-
dexes are orthogonal (uncorrelated). Thus, the
observed variance in cardiac morphology that is
included in the LVH index is statistically indepen-
dent from differences in afterload, body size, and
mass. We used the LVH index to classify LVH into
adaptive or maladaptive patterns. Because the LVH
index is a z-transformed variable, negative LVH index
values reﬂect adaptive stages of LVH, with smaller LV
mass and LVID(d) and greater RWT, whereas positive
LVH index values reﬂect maladaptive stages of LVH
with adverse alteration of LV morphology. The
null value served as a parameterized reference todiscriminate between adaptive and maladaptive LVH
patterns. Kaiser-Guttman criterion was applied to
ascertain the number of extracted factors (Online
Tables S3-A and S3-B).
RESULTS
The study population comprised 128 patients (49%
women). Women and men were at comparable age,
had equal symptoms and New York Heart Association
functional class at referral for AVR, and comparable
cardiovascular risk proﬁle as reﬂected by similar
prevalence of diabetes mellitus, hypertension, and
hyperlipidemia. Cardiac medications were equally
administered in women and men. Coronary artery
sclerosis, chronic obstructive pulmonary disease, or
cerebrovascular accident were observed in a small
portion of the study population, and there were no
signiﬁcant sex differences. Women compared with
men had smaller body size and lower renal function.
Mechanical and larger prosthetic valves were more
frequently implanted in men than in women. Sex
differences abolished after the effective oriﬁce area of
FIGURE 1 Cardiac
Men with aortic ste
Sirius Red staining o
or nondiseased don
men). Nondiseased,
men: n ¼ 14. Scale:
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1076the implanted prosthetic valves was indexed to body
surface area, and there was no evidence of signiﬁcant
sex differences in the occurrence of prosthesis-
patient mismatch after AVR (Table 1).
At the time of AVR, myocardial ﬁbrosis, quantiﬁed
in biopsies from the LV septum, was signiﬁcantly
more pronounced in men with AS compared with
nondiseased men and women with AS (Figures 1A
and 1B). We found in men, but not in women with
AS, a signiﬁcant increase in TGFb-1 protein ex-
pression (Figure 2A) and phosphorylation of SMAD2
(Figure 2B). Phosphorylation of SMAD3 was not
altered in a sex-speciﬁc manner (Figure 2C). Periostin
was signiﬁcantly increased in both sexes with AS,
but was more highly expressed in men compared
with women with AS (Figure 2D).
Before AVR, LVH morphology differed between
women and men with AS. Absolute LV mass andFibrosis in Women and Men With AS
nosis (AS) exhibited increased cardiac ﬁbrosis. (A) Representative
f total collagen; (B) collagen content, quantiﬁed in patients with AS
or hearts. **p < 0.01 (nondiseased vs. AS), #p < 0.05 (women vs.
women: n ¼ 6 versus men: n ¼ 6; AS, women: n ¼ 11 versus
200 mm.LVID(d) were signiﬁcantly larger in men, but sex dif-
ferences were reduced after adjustment for body
surface area. RWT had the tendency to be higher
in women, but the sex difference was of border-
line statistical signiﬁcance (Table 2). We, therefore,
used factor analysis to combine single normalized
parameters of LVH into a composed LVH index.
On the basis of the LVH index, LVH was classiﬁed as
adaptive or maladaptive (see Methods section for
more details). Pre-operatively, adaptive LVH pre-
vailed in women (women: 62% vs. men: 45%) and
maladaptive LVH in men (women: 38% vs. men: 55%,
p < 0.050 for sex difference). This was reﬂected by
slightly greater pre-operative mean LVH indexes in
men than in women (women: 0.08, 95% CI: 0.35 to
0.20 vs. men: 0.09, 95% CI: 0.15 to 0.34; p < 0.360)
(Figure 3).
After AVR, LVH regression occurred in both sexes,
but its pattern was different in women and men.
Adaptive LVH was found after AVR more often in
women (women: 75% vs. men: 49%), whereas mal-
adaptive LVH characterized predominantly men
(women: 25% vs. men: 51%, p < 0.031 for sex differ-
ence). The post-operative mean LVH index remained
greater in men than in women (women: 0.44, 95%
CI: 0.78 to 0.09 vs. men: 0.22, 95% CI: 0.12 to
0.57; p < 0.012) (Figure 3).
Post-AVR survival was similar in both sexes
(overall mortality, women: 17% vs. men: 18%, p <
0.883). However, there was an interaction among
sex, pattern of LVH, and survival (hazard ratio: 0.12,
95% CI: 0.02 to 0.89, p < 0.038). Women with mal-
adaptive LVH at surgery had signiﬁcantly worse sur-
vival than women with adaptive LVH (p < 0.050)
(Figure 4B). In contrast, the pattern of LVH was
not associated with survival in men (p < 0.307)
(Figure 4A).
DISCUSSION
In aortic stenosis, maladaptive LV remodeling with
eccentric LVH, more proﬁbrotic gene expression, and
ﬁbrosis occurs with greater likelihood in men than in
women with isolated AS (5–8,19). Our present study is
well in agreement with these ﬁndings; however, it is
the ﬁrst study to link sex-speciﬁc patterns of
PO-induced LVH to survival after AVR. An impaired
survival was found in women with maladaptive LVH
comparedwithwomenwith adaptive LVH. In contrast,
the pattern of LVH did not affect survival in men. This
suggests that maladaptive LV remodeling has a stron-
ger negative impact in women than in men.
Sex differences in the pre-operative LV remodeling
have implications in the regression of LVH after
FIGURE 2 Sex-Speciﬁc Activation of Proﬁbrotic Markers
(A) Transforming growth factor beta 1 (TGF-b1) and (B) phosphorylation of SMAD2 (pSMAD2) are signiﬁcantly increased in men with aortic stenosis (AS), but
not in women, compared with nondiseased subjects. (C) SMAD3 phosphorylation (pSMAD3) was similar in both sexes. (D) Left ventricular hypertrophy led to
increased periostin expression in both sexes compared with nondiseased donor hearts. In AS, periostin was more highly expressed in men than in women.
***p < 0.001, **p < 0.01 (nondiseased vs. AS), and #p< 0.05 (men vs. women). Nondiseased, women: n ¼ 12 versus men: n ¼ 10; AS, women: n ¼ 14 versus
men: n ¼ 21.
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1077AVR. We showed in a former phase of the current
study that development of more favorable LVH in
women was associated with faster regression in
the early follow-up after AVR (8). We now go beyond
this ﬁnding and conﬁrm a more pronounced LVH
regression in the long-term follow-up. Furthermore,
our study provides evidence that sex differences
occurring early after AVR are sustained in the late
post-operative course, and thus it documentssystematic sex differences in the time course of LVH
regression after AVR.
We also show that higher cardiac ﬁbrosis in
men with AS compared with women is associated
with increased TGF-b1 protein expression and phos-
phorylation of SMAD2. Periostin, a down-stream
target of TGF-b1 signaling and a key regulator of
cardiac ﬁbrosis (20), was more highly expressed in
men as well. In human failing hearts, up-regulated
TABLE 2 LV Morphology and Function Before and Late After AVR
Pre-AVR Post-AVR
Women (n ¼ 63) Men (n ¼ 65) p Value Women (n ¼ 29) Men (n ¼ 39) p Value
LVID(d), mm 48.0  6.9 51.0  5.3 0.004 46.0  4.9 51.0  5.8 <0.001
LVID(d)/BSA, mm/m
2 26.0  3.3 25.0  3.1 0.073 25.0  2.6 25.0  2.4 0.717
LVID(s), mm 30.0  7.8 33.0  7.5 0.064 31.0  5.6 34.0  5.9 0.019
PWT(d), mm 12.0  1.3 12.0  1.3 0.245 12.0  1.2 12.0  1.1 0.121
IVS(d), mm 13.0  1.4 13.0  1.4 0.163 12.0  1.3 13.0  1.2 0.628
RWT 0.50  0.08 0.48  0.07 0.093 0.51  0.07 0.48  0.07 0.059
LV mass, g 227  66 258  56 0.005 207  43 254  51 <0.001
LV mass/BSA, g/m2 125  31 127  27 0.621 114  21 124  24 0.092
LVEF, % 61.0  6.2 58.0  6.6 0.774 60.0  7.8 58.0  7.3 0.098
FS, % 37.0  9.5 36  10 0.680 33.0  7.5 33.0  9.0 0.881
Pmean, mm Hg 57  13 55  12 0.469 15  10 13.0  5.9 0.313
Ppeak, mm Hg 80  20 82  17 0.509 25  16 22.0  9.0 0.287
Values are mean  SD. Bold values indicate statistical signiﬁcance.
BSA ¼ body surface area; FS ¼ fractional shortening; IVS(d) ¼ end-diastolic interventricular septum thickness; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction;
LVID ¼ left ventricular internal dimension at end-diastole (d) and end-systole (s); Pmean ¼ mean pressure gradient; Ppeak ¼ peak pressure gradient; PWT(d) ¼ end-diastolic
posterior wall thickness; RWT ¼ relative wall thickness.
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1078periostin expression is associated with cardiac
ﬁbrosis (21). Higher periostin levels were found in
blood from men compared with women with heart
failure (22). Furthermore, periostin has already been
described as a modulator of cardiac remodeling under
PO in mice (23). We now demonstrated sex differ-
ences in PO-induced up-regulation of periostin and
speculate that lower expression of periostin in the
female heart is associated with less cardiac ﬁbrosis,
tentatively linked to an adaptive LVH.
Analysis of sex differences in the development and
regression of LVH requires the estimation of LV mass,
ventricular diameters, wall thicknesses, and their3 Development of LVH and its Regression After AVR in
and Men
ft ventricular hypertrophy (LVH) index values with their correspond-
dence intervals are given before (n ¼ 128, 49% women) and after
, 43% women) aortic valve replacement (AVR).combined effect. We applied in the current study a
factor analysis to operationalize LVH as a combined
endpoint of LV mass, LVID(d), and RWT changes.
Although the factor analysis is commonly used in
social sciences, it has only recently been used in
biomedical research (24). Factor analysis has the ad-
vantages of combining multiple variables into a single
index at the patient level, facilitating the use of this
index in more complex statistical analyses, and
addressing the behavior of complex biological pro-
cesses better than the use of single variables. With
regard to statistical performance, factor analysis of
echocardiography data was as efﬁcient as a conven-
tional approach, which we applied earlier, to compare
patients’ LV mass and RWT with prognostically-
validated reference values from the general popula-
tion (8). Notably, similar numbers of patients were
needed to establish signiﬁcant sex differences in the
development and regression of LVH. Adequate model
power beyond controlled study design and meticu-
lous selection is an important prerequisite for the
transferability of results.
Clinicians are well aware of strong interindividual
differences in the amount and pattern of LVH. We
now demonstrate that consideration of sex partially
reduces this variability. Adaptive LVH is more com-
mon in women’s hearts, whereas maladaptive LVH
and increased ﬁbrosis are more characteristic of
men’s hearts. This is well in agreement with some
previous observations from us and others (7,8). We
link higher TGF-b1/SMAD2 signaling, periostin
expression, and higher cardiac ﬁbrosis level in men
tentatively with maladaptive remodeling. A better
understanding of the regulatory mechanisms
FIGURE 4 Impact of Sex and Pre-Operative Pattern of LVH on Late Post-AVR Survival
(A) Men with adaptive LVH have similar survival compared with men with maladaptive LVH; (B) women with adaptive LVH have signiﬁcantly
better survival compared with women with maladaptive LVH. Data from 128 patients (49% women) are summarized. LV ¼ left ventricular;
other abbreviations as in Figure 3.
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1079underlying this sex difference offers the potential to
identify a protective pathway in the response of the
heart to PO. This is of particular interest, because
maladaptive LVH in women is associated with worse
survival. Our data suggest that determining whether
earlier intervention in women—before maladaptive
remodeling occurs—is beneﬁcial may be worth eval-
uating. Prospective and retrospective analysis of
large databases may be ﬁrst steps. The same hy-
potheses may be tested in men, but may require
higher numbers for testing.
Alternatively, sex-speciﬁc evidence should be
sought to determine whether women and/or men
with maladaptive remodeling beneﬁt post-operatively
from substances that counteract proﬁbrotic mecha-
nisms, such as angiotensin-converting enzyme in-
hibitors or aldosterone antagonists.
STUDY LIMITATIONS. This study has limited patient
numbers and events, but the statistical impact on the
power of the analysis is largely compensated by the
duration of follow-up and meticulous patient char-
acterization. A further limitation is the small number
of patients at follow-up.CONCLUSIONS
We show for the ﬁrst time that pre-operative LVH
is associated with survival in women. We also iden-
tiﬁed molecular mechanisms underlying sex dif-
ferences in cardiac ﬁbrosis that may contribute
to sex-speciﬁc LV remodeling. The link between
pattern of remodeling and survival raises the ques-
tion of optimizing the management of AS in a sex-
speciﬁc manner, and further evidence, obtained by
analysis of suitable databases and well-designed
clinical trials, is needed.
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